HC Wainwright Has Negative View of Talphera FY2029 Earnings

Key Points

• HC Wainwright lowered its FY2029 EPS estimate for Talphera to $0.12 from $0.13, while maintaining a “Buy” rating and $3.00 price target. The firm forecasts FY2030 EPS of $0.32.
• Analyst sentiment is mixed, with two Buy ratings, one Hold and one Sell; MarketBeat’s consensus is Hold with an average target price of $3.00.
• Talphera shares opened at $1.21, versus a 52-week range of $0.40 to $1.57, and the company reported quarterly EPS of negative $0.06, in line with consensus. Institutional investors own 37.67% of the stock.

Talphera, Inc. (NASDAQ:TLPH - Free Report) - Equities researchers at HC Wainwright dropped their FY2029 earnings per share estimates for Talphera in a research report issued to clients and investors on Thursday, August 13th. HC Wainwright analyst B. Folkes now forecasts that the company will earn $0.12 per share for the year, down from their prior estimate of $0.13. HC Wainwright has a "Buy" rating and a $3.00 price target on the stock. The consensus estimate for Talphera's current full-year earnings is ($0.26) per share. HC Wainwright also issued estimates for Talphera's FY2030 earnings at $0.32 EPS.

Several other equities analysts have also commented on the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of Talphera in a research report on Friday, July 17th. Westpark Capital assumed coverage on shares of Talphera in a research report on Thursday, April 30th. They set a "buy" rating and a $3.00 target price on the stock. Zacks Research upgraded Talphera to a "hold" rating in a research report on Monday, June 8th. Finally, Wall Street Zen raised Talphera to a "hold" rating in a research note on Saturday, August 8th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Talphera presently has a consensus rating of "Hold" and an average target price of $3.00.

Talphera Stock Performance

Shares of TLPH opened at $1.21 on Friday. The company's fifty day moving average is $1.19 and its 200 day moving average is $0.96. Talphera has a fifty-two week low of $0.40 and a fifty-two week high of $1.57. The stock has a market capitalization of $62.80 million, a PE ratio of -4.48 and a beta of 0.69.

Talphera (NASDAQ:TLPH - Get Free Report) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.06) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.06).

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in TLPH. Group One Trading LLC lifted its holdings in Talphera by 3,224.0% during the 3rd quarter. Group One Trading LLC now owns 30,415 shares of the company's stock valued at $27,000 after buying an additional 29,500 shares in the last quarter. Dauntless Investment Group LLC bought a new position in Talphera in the 3rd quarter worth about $89,000. Virtu Financial LLC bought a new position in Talphera in the 3rd quarter worth about $29,000. Nantahala Capital Management LLC increased its position in shares of Talphera by 75.3% during the third quarter. Nantahala Capital Management LLC now owns 3,492,519 shares of the company's stock worth $3,120,000 after acquiring an additional 1,500,000 shares during the period. Finally, AIGH Capital Management LLC increased its position in shares of Talphera by 4.6% during the fourth quarter. AIGH Capital Management LLC now owns 4,661,502 shares of the company's stock worth $5,314,000 after acquiring an additional 206,957 shares during the period. 37.67% of the stock is currently owned by institutional investors.

Talphera Company Profile

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source